Ospemifene: a novel selective estrogen receptor modulator for treatment of dyspareunia.

Abstract

Ospemifene is a novel, oral selective estrogen receptor modulator that has been approved in the USA for treatment of dyspareunia. The decline in estrogen during menopause creates vulvovaginal changes that can cause symptoms that adversely impact women psychosexually. Many women are reluctant to discuss painful sex and providers must proactively inquire about sexuality issues. Ospemifene has been shown to reverse changes associated with vulvovaginal atrophy and relieve symptoms of dyspareunia. Safety studies of treatment up to 52 weeks have shown ospemifene to be safe with no impact on endometrial hyperplasia/carcinoma, venous thrombotic events or pelvic organ prolapse. Further studies are needed to evaluate its role in bone and breast health.

• Authors: Scott Evan Eder
• Journal: Women's health (London, England) (Womens Health (Lond)) Vol. 10 Issue 5 Pg. 499-503 (Sep 2014) ISSN: 1745-5065 [Electronic] United States
• PMID: 25335541 (Publication Type: Journal Article)

Chemical References

• Selective Estrogen Receptor Modulators
• Tamoxifen
• Ospemifene

Topics

• Dyspareunia (drug therapy)
• Female
• Humans
• Middle Aged
• Postmenopause
• Selective Estrogen Receptor Modulators (therapeutic use)
• Tamoxifen (analogs & derivatives, therapeutic use)
• Vagina (drug effects)
• Vulva (drug effects)
• Women's Health